Navigation Links
Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting

s

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Merck Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Merck Serono’s current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on February 28, 2006. These factors include any failure or delay in Merck Serono’s ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, the outcome of any government investigations and litigation. Merck Serono is providing this information as of the date of this press release, and has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

###

About Merck Serono S.A.

Merck Serono S.A. is a global biotechnology leader, with sales in over 90 countries. The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology, with Rebif®, as well as in metabolism and growth, with Saizen®, Serostim® and Zorbtive™. The Company has recently entered the psoriasis area with Raptiva®. Merck Serono's research programs are focused on growing these businesses and on establishing new therapeutic areas
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:4/17/2015)...  Over the next five years, the marijuana industry in ... predicting that 14 more states will legalize recreational marijuana and ... for legal cannabis grew 74 percent in 2014 to $2.7 ... market could grow more than fourfold to $11 billion in ... on marijuana. Cannabiz Mobile Inc. (OTCBB: LGBI) is ...
(Date:4/17/2015)... Today, the Pharmaceutical Research and Manufacturers ... biopharmaceutical companies as "We Work For Health Champions" ... community service. Established in 2009, the ... by the biopharmaceutical industry to honor employees who ... have also shown an outstanding commitment to their ...
(Date:4/17/2015)...   IBA Molecular, a global leader in ... it has signed a definitive agreement to sell its ... to Illinois Health and Science (IHS). Under IHS ownership, IBAM ... headquartered in Dulles, Virginia , and ... product and footprint synergies. IBA Molecular is jointly owned ...
Breaking Medicine Technology:Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... Provider Network presented checks totaling $80,000 to the two ... the Strata Conference in Santa Clara, California. The global ... Once again, the team of "Market Makers" ... Players include David Vogel, CEO and Chief Scientist of ...
... Food and Drug Administration (FDA) has cleared InTone™, a ... "InTone is a true medical breakthrough, and welcome ... issues," said Herschel "Buzz" Peddicord, president & CEO of ... we believe we can effectively treat this condition in ...
Cached Medicine Technology:Heritage Provider Network Awards $80,000 to the Progress Prize Winners in the $3Million Heritage Health Prize Contest at the Strata Conference in Santa Clara, California 2Heritage Provider Network Awards $80,000 to the Progress Prize Winners in the $3Million Heritage Health Prize Contest at the Strata Conference in Santa Clara, California 3Medical Breakthrough for Incontinence From InControl Medical, LLC Cleared by FDA 2
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... 2015 Most dental patients are not ... are made overseas by foreign dental laboratories, according to ... unregulated in more than 40 states by their respective ... of Dental Laboratories has created the “What’s ... patients about the consequences that could be associated with ...
(Date:4/17/2015)... Scientists from the Icahn School ... U.S. and Venezuelan researchers, have discovered the most ... an isolated tribe of Yanomami Amerindians in the ... the Yanomami, previously unexposed to antibiotics or industrialized ... of people living in industrialized countries, and was ...
(Date:4/17/2015)... 2015 Compare-autoinsurance.org has released a new ... online auto insurance quotes . , The online ... for their cars. Drivers should always compare multiple car ... insurance market is a competitive one, which means that ... , It is now possible to compare online ...
(Date:4/17/2015)... 2015 Nomedexamlifeinsurance.com has released a new ... insurance for smokers . , Smoking is linked to ... this, agencies will charge smokers more money for life ... to life insurance and can qualify for advantageous offers. ... for smokers than for non-smokers. Comparing quotes is the ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:National Association Urges Transparency in Dental Industry 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Life Insurance Quotes for Smokers Available Online 2
... to a new study it is observed that reducing blood ... half. It is already known that hypertension (high blood pressure) ... a study carried out by doctors in Dallas, the effect ... ,A group of patients with systolic hypertension - ...
... National Cancer Institute has announced the a new study ... 20 centers around the United States. The study is ... effective in uncovering lung cancer before symptoms start.// ... and there are currently 90 million current and former ...
... to a latest study it is shown that ... a part of their brain responsible for handling ... they often demonstrate// deficits in higher-order thinking abilities, ... response inhibition. These problems lead to the typical ...
... future, infra-red light may enable assessment of blood chemistry ... potential spin-offs for health on the ground.// One of ... Institute, is needle-free blood tests. The space researchers want ... For this purpose, they are looking at near infrared ...
... new study, young women with a self-attacking antibody are ... (aPL) fight a person's own body tissue. //Generally, antibodies ... chance of blood clots, which can lead to an ... researchers conducted a study to determine the connection of ...
... benefits of consuming soy protein has been less explored. According to ... you can use the high protein content of soy in your ... low in saturated fat and cholesterol. If one wants to reduce ... be a good notion to replace soy for some common animal ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: